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CD27, a member of the tumor necrosis factor receptor
superfamily, is constitutively expressed on the majority of
mature T cells, memory B cells, and a portion of NK cells.
Previously we have reported anti-tumor and immunologi-
cal properties of the fully human anti-CD27 mAb 1F5
(CDX-1127) in murine tumor models of solid and hema-
tologic tumors. A Phase I dose escalation study of
CDX-1127 in patients (pts) with recurrent or treatment-
refractory B-cell malignancies and specific solid tumors is
ongoing. CDX-1127 (0.1 to 10 mg/kg IV) was adminis-
tered as a single-dose with 28-day observation, followed
by 4 weekly doses before restaging at Day 85. Up to 4
additional re-treatment cycles (consisting of 4 weekly
doses) were permitted in pts with stable disease or tumor
response. Dose-escalation in pts with solid tumors has
completed with preliminary results as follows: 25 pts
(10 colorectal, 7 melanoma, 3 ovarian, 2 prostate, 2 renal
cell, and 1 NSCLC) received 0.1, 0.3, 1, 3 or 10 mg/kg
CDX-1127, with one DLT (Grade 3 hyponatremia) at
1 mg/kg. Treatment-related toxicity, generally Grade 1-2,
included fatigue, chills, hyperhydrosis, decreased appetite,
rash and diarrhea. Flow cytometry and functional immune
analysis of peripheral blood lymphocytes from these pts
showed evidence of immunomodulatory activity, including
increase in expression of activation markers on T cells
(HLA-DR), increases in NK cells, decrease in Tregs, and
enhanced T cell response to various stimuli in in vitro
assays. Of the 18 pts that completed at least one cycle of
therapy, 4 pts had stable disease (range: 2.4+ to 11+
months), including a renal cell carcinoma pt that has com-
pleted 5 cycles of therapy. To date, no pts have achieved
formal objective response by RECIST. One pt with color-
ectal cancer had 33% shrinkage of measurable disease by
RECIST but this was associated with new lesions; by
irResponse criteria (Wolchok 2009) the patient had irSD
with 45% shrinkage in measurable lesions. This study
shows that weekly dosing of CDX-1127 is well tolerated
with biologic activity. Additional tumor-specific expansion
cohorts (including melanoma and renal cell carcinoma)
are being enrolled to further define the biological and
clinical activity of CDX-1127 as a single-agent.
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